Segment Information (Schedule of Total Revenues of Top Selling Products) (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended	0 Months Ended	3 Months Ended						12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended			9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2013 drug	Sep. 30, 2012 Successor [Member]	Dec. 31, 2013 Successor [Member]	Sep. 30, 2013 Successor [Member]	Jun. 30, 2013 Successor [Member]	Mar. 31, 2013 Successor [Member]	Dec. 31, 2012 Successor [Member]	Dec. 31, 2012 Successor [Member]	Dec. 31, 2013 Successor [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Propafenone (Rythmol SR) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Propafenone (Rythmol SR) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Chlorpheniramine/Hydrocodone (Tussionex) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Chlorpheniramine/Hydrocodone (Tussionex) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Diltiazem (Cardizem CD) [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Diltiazem (Cardizem CD) [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Strativa [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Strativa [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Strativa [Member] Megace ES [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Strativa [Member] Megace ES [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Strativa [Member] Nascobal Nasal Spray [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Strativa [Member] Nascobal Nasal Spray [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Strativa [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Strativa [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2012 Successor [Member] Strativa [Member] Other product related royalty streams [Member] Operating Segments [Member]	Dec. 31, 2013 Successor [Member] Strativa [Member] Other product related royalty streams [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member]	Jun. 30, 2012 Predecessor [Member]	Mar. 31, 2012 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member]	Dec. 31, 2011 Predecessor [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Budesonide (Entocort EC) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Propafenone (Rythmol SR) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Propafenone (Rythmol SR) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Metoprolol Succinate ER (Toprol-XL) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Lamotrigine (Lamictal XR) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Divalproex (Depakote) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Rizatriptan (Maxalt) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Bupropion Er Wellbutrin [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Chlorpheniramine/Hydrocodone (Tussionex) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Chlorpheniramine/Hydrocodone (Tussionex) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Modafinil (Provigil) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Diltiazem (Cardizem CD) [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Diltiazem (Cardizem CD) [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Other [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Par Pharmaceutical [Member] Other product related royalty streams [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Strativa [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Megace ES [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Strativa [Member] Megace ES [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Nascobal Nasal Spray [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Strativa [Member] Nascobal Nasal Spray [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Strativa [Member] Other [Member] Operating Segments [Member]	Sep. 28, 2012 Predecessor [Member] Strativa [Member] Other product related royalty streams [Member] Operating Segments [Member]	Dec. 31, 2011 Predecessor [Member] Strativa [Member] Other product related royalty streams [Member] Operating Segments [Member]
Revenue, Major Customer [Line Items]
Total revenues		$ 10,689	$ 306,281	$ 267,321	$ 233,669	$ 290,196	$ 235,450	$ 246,139	$ 1,097,467	$ 227,312	$ 1,028,418	$ 36,710	$ 198,834	$ 19,623	$ 70,508	$ 31,287	$ 56,670	$ 0	$ 54,577	$ 2,436	$ 46,635	$ 0	$ 45,598	$ 11,255	$ 45,403	$ 17,403	$ 33,518	$ 16,956	$ 27,688	$ 3,702	$ 27,212	$ 79,789	$ 390,346	$ 8,151	$ 31,429	$ 18,827	$ 69,049	$ 10,910	$ 39,510	$ 7,138	$ 26,864	$ 130	$ (910)	$ 649	$ 3,585	$ 238,063	$ 294,333	$ 271,472	$ 803,868	$ 926,138	$ 743,360	$ 834,592	$ 103,762	$ 70,016	$ 53,825	$ 69,835	$ 154,216	$ 250,995	$ 0	$ 0	$ 9,099	$ 0	$ 0	$ 0	$ 34,952	$ 0	$ 30,706	$ 39,481	$ 88,831	$ 0	$ 0	$ 0	$ 249,383	$ 374,288	$ 18,586	$ 29,977	$ 60,508	$ 91,546	$ 38,322	$ 58,172	$ 17,571	$ 21,399	$ 130	$ 3,309	$ 4,485	$ 8,666	[1]
Number of other insignificant generic drugs	50

[1] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.